Single-dose Effect of Intravitreal Dexamethasone Implant for Post-vitrectomy Macular Edema under Silicone Oil.

Abstract

PURPOSE\nTo investigate the single-dose effect of intravitreal dexamethasone (DEX) implant for patients with post-vitrectomy macular edema (ME) under silicone oil (SO) tamponade.\n\n\nMETHODS\nTwelve eyes diagnosed with ME after undergoing pars plana vitrectomy with SO injections were retrospectively reviewed. Each eye received a single intravitreal DEX implant (0.7-mg, Ozurdex; Allergan Inc) injection as treatment for recalcitrant ME. Best-corrected visual acuity (BCVA), central macular thickness (CMT), and intraocular pressure (IOP) were recorded.\n\n\nRESULTS\nCompared with baseline (1.24\xa0±\xa00.34), the mean LogMAR BCVA improved at 1 (1.14\xa0±\xa00.27), 3 (1.13\xa0±\xa00.22), and 6 (1.22\xa0±\xa00.30) months without statistical significance. Maximal CMT resolution was observed at 1\xa0month after intravitreal injection. The CMT value improved significantly at 1 (P =\xa0.008), 3 (P =\xa0.006), and 6 (P =\xa0.009) months. IOP did not show significant elevation during follow-up. No serious adverse events were observed.\n\n\nCONCLUSION\nSingle-dose treatment of DEX implant may have benefit for recalcitrant post-vitrectomy ME under SO tamponade.